Open Access<p>Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial</p>
Author(s) -
Kentaro Machida,
Tomotaka Kawayama,
Masaharu Kinoshita,
Masakazu Ichinose,
Tohru Tsuda,
Shohei Takata,
Hiroshi Kojima,
Makoto Yoshida,
Yoshinori Ashihara,
Masaru Kawashima,
Hideaki Suna,
Hiromasa Inoue
Publication year - 2019
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s223002
Subject(s) - medicine , muscarinic antagonist , crossover study , placebo , copd , pulmonary function testing , pulmonary disease , antagonist , double blind , pharmacology , receptor , pathology , alternative medicine
Although long-acting muscarinic receptor antagonists are central to the management of chronic obstructive pulmonary disease (COPD), inhaled medicines may have technical difficulty in some patients and adherence barriers.